Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 1, 2029

Study Completion Date

February 1, 2030

Conditions

Kaposi SarcomaClassic Kaposi SarcomaRefractory Kaposi Sarcoma

Interventions

DRUG

Pembrolizumab + Lenvatinib

single-arm study of pembrolizumab plus lenvatinib

All Listed Sponsors

lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER